key: cord-0785828-7tarnlso authors: Behlivani, Evangelia; Tragiannidis, Athanasios; Hatzipantelis, Emmanuel; Panagopoulou, Paraskevi title: Immune thrombocytopenia secondary to COVID‐19 infection: Report of two cases date: 2021-06-01 journal: Pediatr Blood Cancer DOI: 10.1002/pbc.29175 sha: a07807df2702375217b5925198286514b4d37cd2 doc_id: 785828 cord_uid: 7tarnlso nan To the Editor: Immune thrombocytopenia (ITP) is well described in childhood, affecting approximately 1.9-6.4 /100,000 children per year. 1 It has been linked to vaccinations and viral infections occurring approximately 1-3 weeks earlier. Recovery time is usually less than 3 months. The suggested management is "watch and wait," but in cases with active mucosal bleeding treatment with corticosteroids and/or intravenous immunoglobulin (IVIG) is recommended. 2 Infection with the severe acute respiratory syndrome-corona virus-2 (SARS-CoV-2) could represent a novel cause of secondary immune phenomena including thrombocytopenia. 3 Herein, we describe two pediatric patients with ITP, temporally and possibly causally, related to a preceding, real-time polymerase chain reaction (RT-PCR) confirmed, COVID-19 infection, presenting in two tertiary hospitals when the second wave of the pandemic swept northern Greece in late 2020. Up to date, only three patients <18 years old with ITP after COVID-19 have been reported. All of them were pre-adolescents/adolescents, with platelets <10,000/µl, no active bleeding, and were treated with IVIG or corticosteroids with adequate clinical/laboratory response. 7, 10, 11 One of the patients presented herein is 3.5 years old, the youngest reported to date. In addition, there are reports of thrombocytopenia cases temporally related to COVID-19 vaccination, raising the question of a possible association. Vigilance is advised among clinicians, as it is still unclear whether this relationship is coincidental or causal. 12, 13, 14 The experience to date is that COVID-19 is associated with immune phenomena via the production of cytokines and autoantibodies, therefore manifestations such as myositis, arthritis, hemolytic anemia, thrombocytopenia, and acute demyelination could be expected after COVID-19. 3 Given these special characteristics of the SARS-CoV-2, it is plausible that it could also trigger childhood ITP, behaving in a way similar to other viruses. Possible pathogenetic mechanisms are similar to other postinfectious and postvaccination ITP, depend on the phase of COVID-19 infection, and include (1) reduced platelet production due to destruction of the bone marrow progenitor cells by the cytokine storm or due to reduced thrombopoietin caused by direct liver damage and (2) increased platelet destruction via production of cross-reacting autoantibodies (via molecular mimicry). During the acute phase of COVID-19 infection, thrombocytopenia has been attributed to platelet consumption due to lung microthrombi. 6, 15, 16 We report these cases to raise awareness among pediatricians and pediatric hematologists to look for evidence of SARS-CoV-2 infection in the period immediately before ITP in order to increase our understanding of the condition. In addition to the previous reports, these patients offer further evidence that ITP could be secondary to COVID-19, similarly to other infections and vaccinations, but unlike other coronaviruses. Additional research is warranted to investigate whether infection with SARS-CoV-2 represents a frank cause of ITP or other immune cytopenias to decipher the role of predisposing factors and to determine whether the clinical course in these patients is the same as post other causes. The incidence of immune thrombocytopenic purpura in children and adults: A critical review of published reports American Society of Hematology 2019 guidelines for immune thrombocytopenia COVID-19 and the clinical course of rheumatic manifestations COVID-19-associated immune thrombocytopenia Immune thrombocytopenic purpura in a patient with Covid-19 Immune thrombocytopenia secondary to COVID-19: a systematic review SARS-CoV-2 infection in two pediatric patients with immune cytopenias: a single institution experience during the pandemic Hematological manifestations of SARS-CoV-2 in children Version: 3/18/21. Access date Severe pediatric COVID-19 presenting with respiratory failure and severe thrombocytopenia Immune thrombocytopenia (ITP) in a pediatric patient positive for SARS-CoV-2 Vigilance regarding immune thrombocytopenic purpura after COVID-19 vaccine SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine Mechanism of thrombocytopenia in COVID-19 patients Mechanisms involved in the development of thrombocytopenia in patients with COVID-19